ESMO 2021: positive data supports Enhertu use in breast cancer treatment
Overall Survival | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive and HR-negative disease
Enhertu (Trastuzumab Deruxtecan): Magic ADC Drug | Biopharma PEG
Trastuzumab Deruxtecan Shows Superior PFS Versus T-DM1 in HER2+ Unresectable/Metastatic Breast Cancer
Enhertu: Most Powerful Drug to Treat Advanced HER2-Positive Breast Cancer • BioPharma Media
Enhertu improves survival in Phase III breast cancer trial
Enhertu Improves Survival for Women with HER2-Positive Breast Cancer - Cancer Health
Overall Survival | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Trastuzumab Deruxtecan Extends Overall Survival in HER2+ Advanced Gastric/GEJ Cancer
Enhertu Effective in HER2-Positive Metastatic Breast Cancer - NCI
Enhertu significantly improved both progression-free and overall survival in DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer – Odisha Diary
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease
ASCO 2022: AstraZeneca, Pfizer, Novartis Share Key Data on Breast Cancer Therapeutics - GeneOnline News
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
ESMO: With massive tumor progression edge, AstraZeneca-Daiichi's Enhertu shows Roche's Kadcyla who's the better breast cancer drug | Fierce Pharma
Results with ENHERTU | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Trastuzumab Deruxtecan Shows Survival Improvement in HER2-positive Metastatic Breast Cancer
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer - NCI
Overall survival after brain metastases (BRM) according to subtype. | Download Scientific Diagram
Enhertu: Most Powerful Drug to Treat Advanced HER2-Positive Breast Cancer • BioPharma Media
